reviewed april 2026|next review october 2026|88 physicians psi has verified|226 published studies
Mechano Growth Factor (MGF)
Mechano growth factor (MGF) is the Ec splice variant of IGF-1 produced in response to mechanical muscle stress, carrying a unique 24-amino-acid C-terminal domain that activates satellite cells (muscle stem cells) for repair and adaptation.
Evidence landscape: 226 published studies
226 published items. 8 human studies and 179 animal studies.
- 8 Human
- 179 Animal
- 13 Reviews
- 26 Other research
Not FDA-approved. MGF is a naturally occurring (the body's own) splice variant of IGF-1. Synthetic MGF peptide (the C-terminal E domain) is available as a research compound. Not available through standard pharmacies or specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.
226 published studies including 8 human studies and 179 animal studies. Human studies document exercise-responsive MGF expression in muscle biopsy tissue. No controlled human trials have tested exogenous synthetic MGF administration.
The unique 24-amino-acid C-terminal E domain activates quiescent satellite cells through a mechanism distinct from classical IGF-1 receptor signaling. Native MGF has a half-life of approximately 5 minutes, limiting therapeutic utility. PEG-MGF (PEGylated Mechano Growth Factor) extends this to hours.
PSI Assessment
When muscles are exercised or mechanically stressed, they produce MGF - a splice variant of IGF-1 that carries a unique 24-amino-acid C-terminal domain not found in any other IGF-1 isoform. This domain activates dormant satellite cells (muscle stem cells) for repair and adaptation through a mechanism distinct from classical IGF-1 receptor signaling. Exercise-responsive expression is documented in human muscle tissue (Goldspink and colleagues). The defining limitations are the extremely short native half-life of approximately 5 minutes and the complete absence of controlled human trials for exogenous synthetic MGF. Whether injecting a synthetic version of this exercise-induced signal replicates the body's own repair response is entirely untested in humans.
The body's own signal for exercise-induced muscle repair. Activates dormant satellite cells. Native half-life of approximately 5 minutes limits therapeutic utility.
The mechanism centers on the unique Ec splice variant C-terminal E domain. When muscle tissue undergoes mechanical stress, alternative splicing of the IGF-1 gene produces MGF with this unique 24-amino-acid extension. The E domain activates quiescent satellite cells - muscle stem cells that sit dormant between the muscle fiber and its surrounding membrane - promoting their proliferation before they differentiate and fuse with existing fibers. This mechanism is distinct from classical IGF-1 receptor signaling, which drives differentiation rather than proliferation. The extremely short native half-life (approximately 5 minutes) led to development of PEG-MGF, a PEGylated form that extends the active period to hours.
What the evidence supports
MGF is the Ec splice variant of IGF-1, produced in response to mechanical muscle stress. The unique 24-amino-acid C-terminal E domain activates quiescent satellite cells through a mechanism distinct from classical IGF-1 receptor signaling. Exercise-responsive expression is documented in human muscle tissue (Goldspink and colleagues). PEG-MGF extends the extremely short native half-life from minutes to hours.
What is not yet established
Whether exogenous synthetic MGF replicates the satellite cell activation produced by the body's own exercise-induced MGF. No controlled human trials exist for any form (native or PEGylated). Whether the approximately 5-minute half-life of native MGF is sufficient for therapeutic effect. Optimal dosing and timing relative to exercise.
Research Evidence
The findings below cover what exercise physiology research has established about the body's own MGF and where the evidence thins for synthetic supplementation.
Evidence by condition
Evidence dimensions across MGF research areas. Muscle repair and hypertrophy have animal data and exercise physiology studies. Injury recovery is community-reported only. No controlled human trials exist for any exogenous MGF application.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Muscle Repair | ||||
| Muscle Hypertrophy | ||||
| Injury Recovery |
The unique 24-amino-acid C-terminal E domain activates quiescent satellite cells through a mechanism distinct from classical IGF-1 receptor signaling. This represents a separate pathway for muscle stem cell activation that is not triggered by systemic IGF-1.
The satellite cell activation mechanism is the primary biological interest in MGF. It suggests a targeted repair signal rather than a systemic growth signal.
Exercise-responsive MGF expression has been documented in human muscle tissue through biopsy studies (Goldspink and colleagues). MGF mRNA increases after resistance exercise and mechanical loading in both animal and human muscle.
The human biopsy data confirms that MGF is a real exercise-responsive signal, not just an animal model finding. However, this documents the body's own response, not the effect of injecting synthetic MGF.
PEG-MGF was developed to address the approximately 5-minute native half-life. PEGylation (attaching a polyethylene glycol polymer) extends the active period from minutes to hours. No controlled human trials exist for either native MGF or PEG-MGF.
The extremely short half-life of native MGF raises fundamental questions about whether exogenous administration can deliver a meaningful biological signal before the peptide is degraded.
8 Human|179 Animal|13 Reviews
View all 226 indexed studiesHow Mechano Growth Factor (MGF) Works
Mechano growth factor (MGF) is a special form of insulin-like growth factor-1, which means it is a variant of one of the body's natural growth signals. Muscles produce it specifically in response to exercise or mechanical stress, and it carries a unique segment that activates dormant muscle stem cells for repair.
When you exercise, your muscles release MGF as a repair signal that wakes up dormant muscle stem cells. Synthetic MGF attempts to boost this natural signal. See MGF peptide page for details.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
MGF is the Ec splice variant of IGF-1 with a unique 24-amino-acid C-terminal E domain. This E domain activates quiescent satellite cells through a mechanism distinct from classical IGF-1R signaling. Expression is mechanically responsive - increasing after resistance exercise and muscle damage. The native half-life is approximately 5 minutes, severely limiting systemic bioavailability. PEG-MGF extends the half-life through PEGylation. Yang and Goldspink characterized MGF as a distinct IGF-1 isoform with unique biological activity focused on satellite cell proliferation rather than differentiation.
What is Mechano Growth Factor (MGF) being studied for?
Researchers are studying Mechano Growth Factor (MGF) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Mechano Growth Factor (MGF) overall. This means a compound can have human studies for one condition but only animal data for another.
Muscle Repair
·PreclinicalThe body's own MGF role in exercise-induced muscle repair is established biology. Whether exogenous synthetic MGF replicates this effect is untested in humans.
Limitations: No controlled human trials for exogenous MGF. The 5-minute native half-life raises questions about bioavailability.
Muscle Hypertrophy
·PreclinicalSatellite cell activation by the MGF E domain is demonstrated in cell culture. Animal studies show enhanced muscle growth. No human hypertrophy trials exist.
Limitations: All hypertrophy data is from cell culture and animal models. The theoretical amplification of exercise-induced growth is unproven.
Injury Recovery
·PreclinicalCommunity use for muscle injury recovery is reported but no clinical trials exist.
Limitations: No clinical evidence. Community use reports are uncontrolled.
Safety and Regulatory Status
FDA Status: Not FDA-approved. MGF is a naturally occurring (the body's own) IGF-1 splice variant. Synthetic MGF peptide is classified as a research compound.
Availability: Available as a research compound from peptide suppliers. PEG-MGF is also available as a research compound. Neither is available through standard pharmacies or specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.
Class context: No human safety data for exogenous MGF. The extremely short native half-life (approximately 5 minutes) limits systemic exposure. PEG-MGF extends the active period but has no human safety data either.
No human safety data exists for exogenous MGF or PEG-MGF. The extremely short native half-life of approximately 5 minutes limits systemic exposure, which is favorable from a safety perspective but raises questions about whether any meaningful biological signal is delivered. As a naturally occurring (the body's own) peptide, MGF has a baseline safety context, but the synthetic form has not been tested in controlled human settings.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Mechano Growth Factor (MGF) discussion.
Comparison and Related Research
MGF is most often compared with other IGF-1 pathway compounds. The comparisons below outline how each differs.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The paper that characterized Mechano-Growth Factor as a distinct splice variant of IGF-1 with unique biological properties. Demonstrated that MGF (the IGF-1 Ec peptide) preferentially activates muscle satellite cell proliferation, while mature IGF-1 primarily drives differentiation. This established MGF as a separate signaling entity from systemic IGF-1.Yang SY & Goldspink G., 2002 in FEBS Lett. View on PubMed
- 2.Measured MGF expression in human muscle biopsies following resistance exercise in young and elderly subjects. Found that MGF mRNA expression was significantly upregulated by exercise in both age groups, but the response was attenuated in older individuals, suggesting an age-related decline in the mechano-sensitive IGF-1 splice variant signaling pathway.Hameed M et al., 2003 in J Physiol. View on PubMed
- 3.A comprehensive review of MGF biology covering its discovery, expression patterns, and proposed roles in tissue repair. The paper synthesized evidence that MGF functions as an early responder to mechanical loading and tissue damage, activating local repair mechanisms before systemic IGF-1 pathways are engaged.Matheny RW Jr et al., 2010 in Endocrinology. View on PubMed
- 4.Investigated MGF administration in a sheep model of acute myocardial infarction. Treatment with MGF peptide reduced the loss of cardiac function compared to controls, suggesting potential cardioprotective applications. The study expanded the known scope of MGF activity beyond skeletal muscle to cardiac tissue repair.Carpenter V et al., 2008 in Heart Lung Circ. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.